Writing from thirty years in precision diagnostics: from biomarker validation to liver longevity and national‑scale precision medicine programmes, including ideas behind my book Precision Diagnostics: A Founder’s Journey.
This is a personal story about longevity medicine seen from the waiting room, framed by the WHO concept of intrinsic capacity and by a life split between Barcelona and the Gulf. A Personal Prelude I don’t think we can truly understand the abstraction of “healthcare infrastructure” until it knocks on our door. Recently, I lost…
by Jose Leal, 5th December 2025 Where should we build the next stage of our work? This question has been driving my thinking about the Gulf for the past year. As Ophiomics moves from clinical validation into manufacturing and regional deployment, I need to understand not just market sizes or tender processes, but what each country’s…
Why Qatar can – and must – claim the diagnostics translation space before regional competitors occupy it By José Pereira Leal, PhD Published on Linkedin on Dec 4th, 2025. Over the past year, I’ve been reflecting – and occasionally writing here – on why I believe the countries of the Gulf Cooperation Council are building…
Published on LinkedIn on Nov 20th In Part 1/2 (https://www.linkedin.com/pulse/rebuilding-case-diagnostics-investment-12-reflections-pereira-leal-swvbf), I discussed why diagnostics face a systematic funding gap despite being essential infrastructure for precision medicine, and outlined five strategic directions for entrepreneurs building diagnostic companies. Those reflections emerged from building Ophiomics and follow from the reflection I’ve been making for my book, Precision Diagnostics:…
Published on LinkedIn on Nov 17th The diagnostics sector faces a paradox: we’re living through a precision medicine revolution, yet the tools that make precision medicine possible remain chronically underfunded. In 2023-2024, diagnostics captured just $2.2 billion in global venture funding, while AI companies raised over $100 billion globally in 2024. Even within healthcare, nearly…
Published on Linkedin on November 8th, 2025 Reading Qatar’s latest precision medicine and national strategy reports as my flight approached Doha, I found myself genuinely impressed and, as a veteran of biomedical strategy, more than a little astonished. In barely a generation, Qatar has accomplished what it has taken the world’s leading medical innovation centers…
At 35, Sarah suffered a heart attack that a €30 genetic test could have prevented. Her story isn’t unusual, it’s a mirror of how health systems worldwide confuse “standard care” with equity. Sarah, a 34-year-old teacher, had visited her GP complaining of fatigue and chest tightness during exercise. Her cholesterol was significantly elevated at 8.2…
“70% of clinical decisions depend on diagnostics.” You’ve seen this statistic, but it hides an important detail: timing. The acuity gradient: Lab testing occurs in 98% of inpatient encounters, 56% in emergency departments, but only 29% in outpatient settings (Ngo et al., 2017): diagnostics concentrate where disease is most advanced. Prevention is neglected: Evidence-based guidelines…
Published on Linkedin on August 3rd, 2025 While everyone chases longevity drugs, the real fountain of youth sits in your liver In the ever-expanding dialogue around longevity in a medical setting, we hear a lot about telomeres, senescence, mitochondrial decline, DNA repair, VO2 Max, stem cells and, unfortunately, an endless stream of pseudo-science powering rising…
published on Linkedin on 20 July 2025. Every week, my LinkedIn feed is filled with billion-dollar AI alliances, breakthrough biomarker announcements, and government blueprints for “future healthcare.” Locally and globally, the numbers are extraordinary: the global precision medicine market is set to reach USD 119 billion in 2025 and leap to USD 470 billion by…